Phaseline

Companies › Minerva Neurosciences

Minerva Neurosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Roluperidone (MIN-101)
Trace amine-associated receptor 1 (TAAR1) agonist
TAAR1Phase 3Negative Symptoms of SchizophreniaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07565428Roluperidone (MIN-101)Phase 3Negative Symptoms of SchizophreniaPsychiatryDec 2027

From the company's SEC filings

Cash and short-term investments of $77m on 2026-09-30; operating cash outflow about $36m a year; runway about 26 months at that burn, to Nov 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TAAR1 (1)

Companies with the same targets

Otsuka Newleos Therapeutics

Companies built like this

LB Pharmaceuticals Reviva Pharmaceuticals Curemark Emalex Biosciences Boston Medical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.